NO983906D0 - Anvendelse av karboniske anhydraseinhibitorer for behandling av makulær ödem - Google Patents

Anvendelse av karboniske anhydraseinhibitorer for behandling av makulær ödem

Info

Publication number
NO983906D0
NO983906D0 NO983906A NO983906A NO983906D0 NO 983906 D0 NO983906 D0 NO 983906D0 NO 983906 A NO983906 A NO 983906A NO 983906 A NO983906 A NO 983906A NO 983906 D0 NO983906 D0 NO 983906D0
Authority
NO
Norway
Prior art keywords
carbonic anhydrase
treatment
macular edema
anhydrase inhibitors
cai
Prior art date
Application number
NO983906A
Other languages
English (en)
Other versions
NO320043B1 (no
NO983906L (no
Inventor
William Eric Sponsel
Alon Harris
Original Assignee
Advanced Res & Tech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605642.9A external-priority patent/GB9605642D0/en
Application filed by Advanced Res & Tech Inst filed Critical Advanced Res & Tech Inst
Publication of NO983906D0 publication Critical patent/NO983906D0/no
Publication of NO983906L publication Critical patent/NO983906L/no
Publication of NO320043B1 publication Critical patent/NO320043B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Eye Examination Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19983906A 1996-02-26 1998-08-25 Anvendelse av karboniske anhydraseinhibitorer for fremstilling av et medikament for behandling eller forebyggelse av makulaer odem eller aldersrelatert makulaer degenerering NO320043B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1225096P 1996-02-26 1996-02-26
GBGB9605642.9A GB9605642D0 (en) 1996-03-18 1996-03-18 Treatment of macular edema
PCT/US1997/002874 WO1997030704A2 (en) 1996-02-26 1997-02-25 Use of carbonic anhydrase inhibitors for treating macular edema

Publications (3)

Publication Number Publication Date
NO983906D0 true NO983906D0 (no) 1998-08-25
NO983906L NO983906L (no) 1998-10-19
NO320043B1 NO320043B1 (no) 2005-10-17

Family

ID=26308946

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19983906A NO320043B1 (no) 1996-02-26 1998-08-25 Anvendelse av karboniske anhydraseinhibitorer for fremstilling av et medikament for behandling eller forebyggelse av makulaer odem eller aldersrelatert makulaer degenerering

Country Status (26)

Country Link
EP (1) EP0954305B9 (no)
JP (1) JP4392481B2 (no)
KR (1) KR100471586B1 (no)
CN (1) CN1225582A (no)
AT (1) ATE239468T1 (no)
AU (1) AU727565B2 (no)
BG (1) BG64525B1 (no)
BR (1) BR9707674A (no)
CA (1) CA2247063C (no)
CZ (1) CZ299509B6 (no)
DE (1) DE69721824T2 (no)
DK (1) DK0954305T3 (no)
EA (1) EA001681B1 (no)
EE (1) EE03804B1 (no)
ES (1) ES2199348T4 (no)
HU (1) HU227161B1 (no)
IL (1) IL125912A0 (no)
IS (1) IS2053B (no)
MX (1) MXPA98006961A (no)
NO (1) NO320043B1 (no)
NZ (1) NZ331843A (no)
PT (1) PT954305E (no)
SK (1) SK284371B6 (no)
TR (1) TR199801665T2 (no)
WO (1) WO1997030704A2 (no)
YU (1) YU49422B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
CA2323749A1 (en) * 1998-03-06 1999-09-10 William E. Sponsel Composition and method for treating macular disorders
US5948801A (en) * 1998-03-09 1999-09-07 Alcon Laboratories, Inc. Treatment of retinal edema with brinzolamide
KR20010071827A (ko) * 1998-07-10 2001-07-31 앤더슨 데릭 제이. 반점성망막 퇴행에서 신혈관 신생의 예방치료
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US20100063035A1 (en) 2006-12-15 2010-03-11 Nicox S.A. Carbonic anhydrase inhibitors derivatives
AR084194A1 (es) * 2010-12-09 2013-04-24 Fovea Pharmaceuticals Derivados de arilsulfonamida para la prevencion o el tratamiento de trastornos oftalmologicos especificos
JP2020504711A (ja) 2016-12-21 2020-02-13 バイオセリックス， インコーポレイテッド タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797413A (en) * 1986-05-14 1989-01-10 Merck & Co., Inc. Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
GB2223166B (en) * 1988-09-29 1992-03-18 American Cyanamid Co Stable ophthalmic preparations containing methazolamide
US5153192A (en) * 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors

Also Published As

Publication number Publication date
WO1997030704A3 (en) 1997-09-25
PT954305E (pt) 2003-09-30
EP0954305B1 (en) 2003-05-07
EP0954305A2 (en) 1999-11-10
NO320043B1 (no) 2005-10-17
HUP9902054A3 (en) 2001-07-30
BG64525B1 (bg) 2005-06-30
SK284371B6 (sk) 2005-02-04
CA2247063A1 (en) 1997-08-28
IS2053B (is) 2005-10-14
EP0954305B9 (en) 2010-08-04
CA2247063C (en) 2004-01-06
ES2199348T3 (es) 2004-02-16
JP4392481B2 (ja) 2010-01-06
JP2000506833A (ja) 2000-06-06
MXPA98006961A (es) 2004-11-19
NZ331843A (en) 2000-09-29
DK0954305T3 (da) 2003-08-25
TR199801665T2 (xx) 1998-12-21
HUP9902054A1 (hu) 2000-03-28
IS4829A (is) 1998-08-20
KR100471586B1 (ko) 2005-07-11
WO1997030704A2 (en) 1997-08-28
AU1972197A (en) 1997-09-10
EE03804B1 (et) 2002-08-15
YU49422B (sh) 2006-01-16
YU35398A (sh) 2001-12-26
CZ299509B6 (cs) 2008-08-20
CZ269998A3 (cs) 2000-01-12
AU727565B2 (en) 2000-12-14
EA199800764A1 (ru) 1999-06-24
IL125912A0 (en) 1999-04-11
HU227161B1 (en) 2010-09-28
KR19990087242A (ko) 1999-12-15
BR9707674A (pt) 2000-01-04
EA001681B1 (ru) 2001-06-25
NO983906L (no) 1998-10-19
ES2199348T4 (es) 2010-10-19
SK115198A3 (en) 2000-01-18
BG102797A (en) 1999-09-30
CN1225582A (zh) 1999-08-11
ATE239468T1 (de) 2003-05-15
DE69721824D1 (de) 2003-06-12
EE9800263A (et) 1999-08-16
DE69721824T2 (de) 2004-03-11

Similar Documents

Publication Publication Date Title
NO983906D0 (no) Anvendelse av karboniske anhydraseinhibitorer for behandling av makulær ödem
NZ309523A (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
WO2000040235A3 (en) Treatment of asthma with mek inhibitors
DE69311101D1 (de) Verfahren sowie anordnung zum herstellen von wundverbänden sowie mit diesem verfahren hergestellter wundverband
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
UA66757C2 (en) Ophthalmologic composition of carbonic anhydrase inhibitors, method for treating or preventing macular edema or age-related macular degeneration
AU2001280093A1 (en) Method for the prevention and treatment of retinopathy
EE9700350A (et) COMT-inhibiitorite uus kasutamine ja diabeetiliste vaskulaarsete häirete ärahoidmise meetod
WO2001034546A3 (en) Omega chain modified 15-hydroxyeicosatetraenoic acid derivatives and methods of their use for the treatment of dry eye
DE69412178T2 (de) Apparat zur Behandlung von Lagen
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
NO984198L (no) FremgangsmÕte for behandling av aggresjon
SE9602145D0 (sv) New improved formulation for treatment of thromboembolism
WO2002005796A3 (en) Use of a spla2 inhibitor for the treatment of sepsis
RU94042315A (ru) Способ лечения язвенной болезни желудка и двенадцатиперстной кишки
NO984190L (no) FremgangsmÕte for behandling av insomnia
AUPR204400A0 (en) Method and apparatus for the treatment of neoplastic growths

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees